Skip to the page

Data / Federal grants / PAR-25-183

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

National Institutes of Health (Department of Health and Human Services) is accepting applications until October 15, 2027.

SpecStream is the live web data engine for teams and agents. It reads every open and forecast federal opportunity on Grants.gov each morning, and this page is that reading. Describe your organization once and the grants that fit arrive in your sheet, CRM, Slack or agent as they are posted.

Key facts

Opportunity number
PAR-25-183
Status
Posted, open
Posted
November 26, 2024
Closes
October 15, 2027
Cost sharing
Not required
Funding instrument
Grant
Category
Health
Assistance listing
93.242 Mental Health Research Grants; None None
Contact
National Institutes of Health · [email protected] · 301-402-2541

Who can apply

  • Small businesses
  • For profit organizations other than small businesses
  • Special district governments
  • Public housing authorities/Indian housing authorities
  • Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
  • City or township governments
  • Native American tribal governments (Federally recognized)
  • Others (see text field entitled "Additional Information on Eligibility" for clarification)
  • County governments
  • Public and State controlled institutions of higher education
  • Private institutions of higher education
  • Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
  • Independent school districts
  • Native American tribal organizations (other than Federally recognized tribal governments)
  • State governments

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

What the agency says

NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this NOFO encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this NOFO is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

The notice on Grants.gov Full announcement

Other open grants from the Department of Health and Human Services

All grants open to Small businesses · All grants open to For profit organizations other than small businesses · All grants open to Special district governments · Everything closing in October 2027

Read from the Grants.gov API, last updated 2026-10-23. The agency's notice on Grants.gov is the official record; check it before you apply.